Director: Mitch A. Phelps, PhD
Senior Faculty Advisor: Michael Grever, MD
The Pharmacoanalytic Shared Resource (PhASR) supports pre-clinical and clinical drug development at Ohio State by providing high quality and cost-effective bioanalytical method development, quantitative sample analysis, and pharmacokinetic/pharmacodynamic experimental design, data analysis and modeling. Expertise among PhASR personnel includes quantitative pharmacology; bioanalytical methodology, design and conduct of pharmacokinetic/pharmacodynamic studies in animal disease models and in humans enrolled in clinical trials; data analysis and modeling of PK/PD data to inform drug development decisions. PhASR personnel are available for consultation on clinical or pre-clinical PK/PD experimental design and analysis.
Provide the OSUCCC – James and broader research and drug development community with:
- High-quality, state-of-the-art, cost-competitive analytical expertise and instrumentation for quantitation of drugs and metabolites in biological specimens
- Pharmacokinetic data (real-time when necessary) to enable pharmacologic data to be incorporated into clinical decision-making during dose escalation and interpretation of patient response and toxicity or in pre-clinical drug development efforts
- Expertise in pharmacokinetic/pharmacodynamic study design and data interpretation during submission of clinical protocols, grant proposals, study reports and publications
Mitch Phelps, PhD, director for the PhASR, is an associate professor with appointments in Ohio State's College of Pharmacy, Division of Pharmaceutics, and College of Medicine, Department of Pharmacology. Phelps has been with the OSUCCC – James for nine years, applying his expertise in analytical methodologies, pharmacokinetic/pharmacodynamic (PK/PD) study design, data analysis and modeling. A supporter of the establishment of PhASR in 2005, he drove its initial development in his previous roles as operations manager and technical director. In his current role, Phelps directs PhASR activities to develop collaborative research projects with other investigators, support PK/PD experimental design, modeling and data analysis, and ensure that resources are utilized efficiently to support high-impact science. His independent research focuses on developing drug therapies to treat cancer and understanding the sources of variability in outcomes of patients treated with anticancer and immunomodulatory agents. He is principal investigator and co-investigator on several research grants funded by the NIH and other public and private organizations. Phelps earned his PhD in Biophysics from Ohio State and completed postdoctoral training in clinical pharmacology under the mentorship of James Dalton, PhD. Prior to completing doctoral training, Phelps spent eight years as a chemist in private industry.
Christopher Coss, PhD, is a research assistant professor in the College of Pharmacy and technical director of The Ohio State University Comprehensive Cancer Center Pharmacoanalytical Shared Resource (PhASR). Coss has expertise in both industrial and academic drug development. Prior to joining OSU, he spent eight years working in the Drug Discovery group at GTx, Inc., a pharmaceutical company that develops small-molecule drugs targeting cancer growth pathways. As a research scientist at GTx, he was involved in the discovery, mechanistic characterization, preclinical and clinical safety and efficacy testing of several novel cancer therapeutics. In addition to overseeing the daily operations of the PhASR, Coss applies his expertise in drug development and clinical pharmacology to meet the diverse needs of the many investigators within the Comprehensive Cancer Center.
Yonghua Ling, PhD, research associate, is a project leader within the PhASR who supports the design and conduct of studies aimed at characterizing absorption, distribution, metabolism and excretion (ADME) properties of novel agents in preclinical and early-phase clinical development. She has extensive experience using liquid chromatography - tandem mass spectometry (LC-MS/MS) for drug and metabolite quantification in biological matrices for the study of drug metabolism, absorption and distribution in animal models and in humans. Ling received her MS in analytical chemistry from Zhongshan University in China and her PhD in physical chemistry from the University of Miami. She completed postdoctoral training in cancer drug pharmacology at Ohio State under the direction of Kenneth Chan, PhD.
Ming Poi, PharmD, PhD, is an assistant professor in the College of Pharmacy and a specialty practice pharmacist for the Investigational Drug Service (IDS) Pharmacy and Phase 1 Clinical Treatment Unit (CTU) in The James Cancer Hospital and Solove Research Institute. Poi supports the design of clinical pharmacokinetic (PK), pharmacodynamic (PD) and pharmacogenetic (PG) studies, development of clinical protocols and PK/PD/PG data analysis. In addition, she supports the design and conduct of non-clinical studies aimed at identifying genetic factors associated with variability in outcomes for patients enrolled in clinical studies at The James. Poi received her PhD in biochemistry (protein sciences) from Ohio State under the mentorship of Ming-Daw Tsai, PhD. She then obtained her PharmD from Ohio State’s College of Pharmacy and served both a pharmacy practice residency (PGY-1) at Ohio State’s Wexner Medical Center and a two-year pharmacy translational research fellowship at the OSUCCC – James.
Jiang Wang, PhD, research associate, is a project leader within the PhASR and supports bioanalytical assay development/validation, design and conduct of preclinical and clinical pharmacology studies of novel anticancer and other agents. He has extensive expertise in quantification of small molecules and peptides in biological matrices by LC-MS/MS and other quantitative technologies that he applies to support preclinical and clinical pharmacology studies critical in the drug-development process in collaboration with investigators at Ohio State and other institutions. After receiving his PhD in pharmacology from Jilin University in China, he completed postdoctoral training in molecular biology at Princeton University under the guidance of Manuel Llinás, PhD, and at Ohio State in pharmaceutics under the direction of Kenneth Chan, PhD.